Updated from Sept. 22 at 7:48 pm ET with additional news about Tekmira and its experimental ebola therapy. Correction: Dirk Haussecker does not own Tekmira shares, as previously reported in error.
NEW YORK (TheStreet) -- Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' (TKMR) experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed in a statement Monday night.
Monday's announcement confirms speculation bandied around Twitter and stock message boards about Tekmira's involvement in the treatment of Sacra, who was stricken with Ebola while treating patients in West Africa. Before Monday, doctors treating Sacra would only say that his care included an experimental therapy without disclosing its name. Sacra was also treated with serum derived from the blood of Dr. Kent Brantly, another Ebola survivor.
Must Read: 10 Stocks George Soros Is Buying
While expressing gratitude for the availability of Tekmira's TKM-Ebola, Nebraska Medical Center warned against drawing conclusions about which therapy (or therapies) assisted in Sacra's recovery from Ebola.
"We need to carefully assess all the treatments being provided to patients with the Ebola virus," Dr. Angela Hewlett, associate medical director of the Biocontainment Unit at The Nebraska Medical Center in Omaha, said in a statement. "We don't know if it was Dr. Sacra's own immune system, the supportive therapy we provided, the blood transfusion from Dr. Brantly, TKM-Ebola or a combination off all these factors that helped Dr. Sacra recover. What's important is that we pool all of our treatment resources and continue to study what is most effective in treating the virus."